Aurinia starts PRESERVE trial combining LUPKYNIS with biologics in lupus nephritis
The company raised 2026 revenue guidance and reported a new Phase 4 study pairing LUPKYNIS with belimumab, obinutuzumab or anifrolumab.
SEC filing
2 stories
The company raised 2026 revenue guidance and reported a new Phase 4 study pairing LUPKYNIS with belimumab, obinutuzumab or anifrolumab.
SEC filing
The neuromedicines company said Miller starts as CFO effective September 2, 2026, ahead of pivotal NOVA-2 trial results for LB-102 in schizophrenia.
SEC filing